Plain-English translation of NCT07728474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether LCS103, an herbal formula taken by mouth, can help prevent non-muscle invasive bladder cancer from coming back after surgery. Half of the 60 participants will take this medication twice daily for one year along with their standard care, while the other half will receive standard care alone. Researchers want to see if the medication is safe and whether it works better than standard care by itself.
Even after surgery to remove bladder tumors, this type of cancer often comes back. Doctors use different treatments like special bladder instillations or frequent follow-up scans depending on the cancer's risk level, but new options are needed to better prevent recurrence and reduce the burden of repeated procedures.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to either take the herbal medication (three tablets twice daily) or standard care alone for one year. Both groups will also receive their regular recommended care, which may include office procedures, bladder instillations, or imaging tests depending on your cancer's risk level. The study lasts about two years total, with visits for check-ups, scans, and urine tests scheduled according to your cancer risk group.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Israel